Is cosentyx safe in pregnancy?

Does Cosentyx increase risks during pregnancy?

Cosentyx contains secukinumab, a monoclonal antibody that blocks interleukin-17A. Clinical data on its use in pregnant women remain limited because pregnant patients were excluded from original trials. Post-marketing surveillance and registry data suggest no clear signal of major birth defects, miscarriage, or growth problems, but the numbers are small. Animal studies at doses far above human levels showed no teratogenicity.

How do doctors weigh options when a patient becomes pregnant on Cosentyx?

Doctors usually stop Cosentyx once pregnancy is confirmed unless the disease is severe enough that the mother’s health would suffer without treatment. The antibody crosses the placenta mainly in the second and third trimesters, so exposure during early organ development is often minimal. Some rheumatologists continue treatment if stopping would cause a flare that could harm both mother and fetus.

What guidelines exist for biologics like Cosentyx in pregnancy?

Current European and American rheumatology guidelines classify secukinumab as compatible with pregnancy only when maternal benefit clearly outweighs fetal risk. The FDA label advises using it only if the “potential benefit justifies the potential risk.” No dedicated pregnancy registry exists solely for Cosentyx, but data are collected through the Janssen Pregnancy Exposure Registry and general biologics registries.

Can women breastfeed while taking Cosentyx?

Secukinumab excretion into breast milk is very low and antibodies in milk are broken down by the infant digestive system. Early registry data show no adverse effects in breastfed infants. Doctors usually advise continuing Cosentyx if the patient needs it for disease control, but monitor the infant for infection susceptibility.

When does the Cosentyx patent expire?

The main U.S. compound patent expires in 2026, with possible pediatric exclusivity pushing it to 2027. At https://www.drugpatentwatch.com you can track additional formulation and method-of-use patents that may delay generic or biosimilar entry.

What alternatives exist if Cosentyx must be stopped?

TNF inhibitors such as certolizumab pegol and etanercept have larger pregnancy datasets and are often preferred when treatment must continue. Local corticosteroids, topical treatments, or phototherapy remain safe options for skin psoriasis during pregnancy.